Format

Send to

Choose Destination
J Infect Dis. 2014 Jan 15;209(2):183-91. doi: 10.1093/infdis/jit449. Epub 2013 Oct 7.

A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.

Author information

1
Infant Botulism Treatment and Prevention Program, California Department of Public Health, Richmond, California.

Abstract

BACKGROUND:

Clostridium botulinum strain IBCA10-7060, isolated from a patient with infant botulism, produced botulinum neurotoxin type B (BoNT/B) and another BoNT that, by use of the standard mouse bioassay, could not be neutralized by any of the Centers for Disease Control and Prevention-provided monovalent polyclonal botulinum antitoxins raised against BoNT types A-G.

METHODS AND RESULTS:

 The combining of antitoxins to neutralize the toxicity of known bivalent C. botulinum strains Ab, Ba, Af, and Bf also failed to neutralize the second BoNT. Analysis of culture filtrate by double immunodiffusion yielded a single line of immunoprecipitate with anti-A, anti-B, and anti-F botulinum antitoxins but not with anti-E antitoxin. A heptavalent F(ab')2 botulinum antitoxin A-G obtained from the US Army also did not neutralize the second BoNT. An antitoxin raised against IBCA10-7060 toxoid protected mice against BoNT/B (Okra) and against the second BoNT but did not protect mice against BoNT/A (Hall) or BoNT/F (Langeland).

CONCLUSION:

The second BoNT thus fulfilled classic criteria for being designated BoNT/H. IBCA10-7060 is the first C. botulinum type Bh strain to be identified. BoNT/H is the first new botulinum toxin type to be recognized in >40 years, and its recognition could not have been accomplished without the availability of the mouse bioassay.

KEYWORDS:

Clostridium botulinum; botulinum antitoxin; botulinum toxin; botulism; mouse bioassay

PMID:
24106296
DOI:
10.1093/infdis/jit449
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center